Table 4.
Clinical characteristics at randomization of patients with type 2 diabetes of BENEDICT phase A according to p.Glu936Asp CFH polymorphism.
| Asp/Asp homozygotes | Glu/Glu+Glu/Asp | |
|---|---|---|
| n | 36 | 1,122 |
| Age (years) | 63.4 (9.2) | 62.2 (8.1) |
| Sex (male) | 22 (61.1%) | 585 (52.1%) |
| BMI | 28.3 (26.1–32.5) | 28.4 (25.8–31.6) |
| Diabetes duration (years) | 7 (3–11.5) | 6 (3–11) |
| Hypertension duration (years) | 0.5 (0–7) | 2 (0–8) |
| Smokers (current/former) | 20 (55.6%) | 463 (41.3%) |
| HbA1c (%) | 5.8 (5.2–7.4) | 5.6 (4.8–6.5)* |
| Glucose (mg/dl) | 162.5 (40.1) | 161.4 (47.1) |
| SBP (mmHg) | 149.0 (14.5) | 150.9 (14.1) |
| DBP (mmHg) | 85.9 (7.6) | 87.6 (7.6) |
| MAP (mmHg) | 106.9 (8.7) | 108.7 (8.3) |
| Serum creatinine (mg/dl) | 0.92 (0.17) | 0.91 (0.16) |
| Triglycerides (mg/dl) | 137 (92–202) | 125 (92–179) |
| Total cholesterol (mg/dl) | 209.2 (22.7) | 209.7 (37.0) |
| HDL cholesterol (mg/dl) | 43 (36–57) | 45 (38–54) |
| LDL cholesterol (mg/dl) | 163.6 (25.2) | 162.8 (36.1) |
| UAE (μg/min) | 5.0 (3.6–9.2) | 5.3 (3.6–9.3) |
| ACEi at randomization (yes) | 21 (58.3%) | 553 (49.3%) |
Continuous variables are expressed as mean and SD and compared using unpaired t test or expressed as median and IQR and compared using Mann–Whitney test. Categorical variables are expressed in percentage and compared using Chi-square test or Fisher’s exact test as appropriate.
*P < 0.05 vs Asp/Asp homozygotes.
HbA1c, glycosylated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; UAE, urinary albumin excretion; MAP, mean arterial pressure; LDL, low-density lipoprotein; BMI, body mass index.